BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martins AM, Ascenso A, Ribeiro HM, Marto J. Current and Future Therapies for Psoriasis with a Focus on Serotonergic Drugs. Mol Neurobiol 2020;57:2391-419. [DOI: 10.1007/s12035-020-01889-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Mnekin L, Ripoll L. Topical Use of Cannabis sativa L. Biochemicals. Cosmetics 2021;8:85. [DOI: 10.3390/cosmetics8030085] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Michiels C, Puigdevall L, Cochez P, Achouri Y, Cheou P, Hendrickx E, Dauguet N, Blanchetot C, Dumoutier L. A Targetable, Noncanonical Signal Transducer and Activator of Transcription 3 Activation Induced by the Y-Less Region of IL-22 Receptor Orchestrates Imiquimod-Induced Psoriasis-Like Dermatitis in Mice. J Invest Dermatol 2021:S0022-202X(21)01227-6. [PMID: 33992648 DOI: 10.1016/j.jid.2021.04.016] [Reference Citation Analysis]
3 Rapalli VK, Waghule T, Gorantla S, Dubey SK, Saha RN, Singhvi G. Psoriasis: pathological mechanisms, current pharmacological therapies, and emerging drug delivery systems. Drug Discov Today 2020;25:2212-26. [PMID: 33011340 DOI: 10.1016/j.drudis.2020.09.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
4 Biswasroy P, Pradhan D, Kar B, Ghosh G, Rath G. Recent Advancement in Topical Nanocarriers for the Treatment of Psoriasis. AAPS PharmSciTech 2021;22:164. [PMID: 34041632 DOI: 10.1208/s12249-021-02057-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 El-Gogary RI, Ragai MH, Moftah N, Nasr M. Oleuropein as a novel topical antipsoriatic nutraceutical: formulation in microemulsion nanocarrier and exploratory clinical appraisal. Expert Opin Drug Deliv 2021;:1-10. [PMID: 34010073 DOI: 10.1080/17425247.2021.1932813] [Reference Citation Analysis]
6 Thakur V, Mahajan R. Novel Therapeutic Target(s) for Psoriatic Disease. Front Med 2022;9:712313. [DOI: 10.3389/fmed.2022.712313] [Reference Citation Analysis]
7 Melnikov M, Sviridova A, Rogovskii V, Oleskin A, Boziki M, Bakirtzis C, Kesidou E, Grigoriadis N, Boykо A. Serotoninergic system targeting in multiple sclerosis: the prospective for pathogenetic therapy. Mult Scler Relat Disord 2021;51:102888. [PMID: 33756440 DOI: 10.1016/j.msard.2021.102888] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Maddheshiya S, Ahmad A, Ahmad W, Zakir F, Aggarwal G. Essential oils for the treatment of skin anomalies: Scope and potential. South African Journal of Botany 2022. [DOI: 10.1016/j.sajb.2021.12.034] [Reference Citation Analysis]
9 Cervantes-Durán C, Avalos-Viveros M, Torner L, Sánchez-Ceja SG, Rodríguez-Orozco AR, Martínez-Flores HE, García-Pérez ME. The 5-HT1A receptor agonist, 8-OH-DPAT, attenuates long-lasting pain in imiquimod-induced psoriasis in mice. Exp Dermatol 2021. [PMID: 34726306 DOI: 10.1111/exd.14492] [Reference Citation Analysis]